CFTR and cystic fibrosis: We have previously demonstrated that Ivacaftor (VX-770), which is already used for the treatment of CF patients bearing plasma-resident CFTR mutants [65–69], can prevent P31-43 binding to CFTR, thus opposing the gliadin-induced CFTR malfunction with its pro-inflammatory consequences [12].